Hadassah

Hadassah-Developed Autoimmune Disease Drug Proves Safe in Phase I Clinical Trial

Thursday, Aug 6 2015

A drug developed at the Hadassah Medical Organization to help modulate the effects of autoimmune diseases such as rheumatoid arthritis has proven safe in a Phase I clinical trial at Hadassah. Manufactured by Protalix BioTherapeutics of Carmiel, Israel, the drug, PRX-106, proved to activate T cells, which have a central role in maintaining a well-functioning immune system.

"The results are very exciting and encouraging,” reports Prof. Yaron Ilan of Hadassah’s Internal Medicine Department A and a specialist in immunology and liver disease. “PRX-106 has the potential to be an effective agent for numerous immune-mediated disorders."

This Phase I trial tested the safety and tolerability of PRX-106 in healthy volunteers. With three separate cohorts receiving different doses of the protein compound for five consecutive days, the results demonstrated that oral administration of PRX-106 is safe and well tolerated in all three doses. In addition, researchers observed that PRX-106 triggered the action of various subsets of T cells, some of which are correlated with an anti-inflammatory response.

Preclinical studies with PRX-106 proved to alleviate both immune-mediated hepatitis and colitis in a mouse model, enhancing serum levels of regulatory T-cells and significantly improving clinical arthritis parameters, such as joint inflammation, swelling, and tissue degradation.

PRX-106 uses plant cells as a natural capsule for this protein compound. Protaliz anticipates that it will initiate the next phase of clinical trials with patients at the end of the year.

Comments

From: Gila on September 10, 2015
Would this drug also be one that could be effective in treating Crohn's Disease patients? As is now true of the RA drugs that work with T cells and the autoimmune system? Which I now inject....the oral/pill form sounds much more tolerable considering my Dr. says I will need to continue my therapy for life!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.

READ MORE ›
alt_text

Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

READ MORE ›
alt_text

Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›
alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More